Suppressive activity of macrolide antibiotics on nitric oxide production by lipopolysaccharide stimulation in mice

Mediators of Inflammation

Volumn 12, Issue 4, 2003, Pages 195-202

  Terao, Hajime ^a   Asano, Kazuhito ^a   Kanai, Ken Ichi ^a   Kyo, Yoshiyuki ^a   Watanabe, So ^a   Hisamitsu, Tadashi ^a   Suzaki, Harumi ^a  

^a SHOWA UNIVERSITY   (Japan)

Author keywords

In vivo; Inducible nitric oxide synthase mRNA; Macrolide antibiotics; Mouse; Nitric oxide; Pro inflammatory cytokine; Suppression

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; JOSAMYCIN; LIPOPOLYSACCHARIDE; MACROLIDE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; ROXITHROMYCIN; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG ACCUMULATION; DRUG EFFICACY; DRUG MECHANISM; IN VIVO STUDY; INFLAMMATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; ANTI-BACTERIAL AGENTS; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LIPOPOLYSACCHARIDES; MACROLIDES; MALE; MICE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; REACTIVE NITROGEN SPECIES;

ANIMALIA;

EID: 0142125230     PISSN: 09629351     EISSN: None     Source Type: Journal    
DOI: 10.1080/09629350310001599620     Document Type: Article

References (25)

1. Iino Y, Toriyama M, Kudo K, et al. Erythromycin inhibition of lipopolysaccharide-stimulated tumor necrosis factor alpha production by human monocytes in vitro. Ann Otol Rhinol Laryngol 1992; 101(Suppl 157): 16-20.
2. Keicho N, Kudoh S. Diffuse panbronchiolitis: role of macrolides in therapy. Am J Respir Med 2002; 1: 119-131.
3. Jaffe A, Francis J, Rosental M, et al. Long-term azithromycin may improve lung function in children with cystic fibrosis. Lancet 1998; 351: 420.
4. Altschuler EL. Azithromycin, the multidrug-resistant protein, and cystic fibrosis. Lancet 1998; 351: 1286.
5. Suzaki H, Asano K, Ohki S, Kanai K, Mizutani T, Hisamitsu T. Suppressive activity of a macrolide antibiotic, roxithromycin, on proinflammatory cytokine production in vitro and in vivo. Med Inflamm 1999; 8: 199-204.
6. Asano K, Kamakazu K, Hisamitsu T, Suzaki H. Modulation of Th2 type cytokine production from human peripheral blood leukocytes by a macrolide antibiotic, roxithromycin, in virro. Int Immunopharmac 2001; 1: 1913-1921.
7. Ichikawa Y, Koga H, Tanaka M, et al. Neutrophilia in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis. Chest 1990; 98: 917-923.
8. Shimane T, Asano K, Suzuki M, Hisamitsu T, Suzaki H. Influence of a macrolide antibiotic, roxithromycin, on mast cell growth and activation in vitro. Med Inflamm 2001; 10: 232-332.
9. Muranaka H, Suga M, Sato K, et al. Superoxide scavenging activity of erythromycin-iron complex. Biochem Biophys Res Commun 1997; 232: 183-187.
10. Konno S, Adachi M, Asano K, et al. Influence of roxithromycin on cell-mediated immune responses. Life Sci 1992; 51: PL107-PL112.
11. Tayler BS, Geller DA. Regulation of the inducible nitric oxide synthase (iNOS) gene. In: Salvemin D, Billiar TR, Vodovota Y, eds. Nitric Oxide and Inflammation. Basel: Birkhauser Verlag, 2001: 1-27.
12. Moncada S, Palmer RM, Higgs EA, Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43: 109-142.
13. Lundberg JON, Farkas-Szallasi T, Weitzberg E, et al. High nitric oxide production in human paranasal sinuses. Nat Med 1995; 1: 370-373.
14. Zoritch B. Nitric oxide and asthma. Arc Dis Child 1995; 72: 259.
15. Kooy NW, Royall JA, Ye YZ, Kelly DR, Beckman JS. Evidence for in vivo peroxinitrite production in human acute lung injury. Am J Respir Crit Care Med 1995; 151: 1250-1254.
16. Ianaro A, Ialenti A, Maffia P, et al. Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther 2000; 292: 156-163.
17. Asano K, Kamakazu K, Hisamitsu T, Suzaki H. Suppressive activity of macrolide antibiotics on nitric oxide production from nasal polyp fibroblasts in vitro. Acta Otolaryngol 2003; 123: 1-6.
18. Kudoh S, Uetake T, Hagiwara K, et al. Clinical effects of low-dose and long-term erythromycin chemotherapy on diffuse panbronchiolitis. Nihon Kyobu Shikkan Gakkai Zasshi 1987; 25: 63-69.
19. Cuzzocre S. Role of nitric oxide and reactive oxygen species in arthritis. In: Salvemin D, Billiar TR, Vodovota Y, eds. Nitric Oxide and Inflammation. Basel: Birkhauser Verlag, 2001: 145-160.
20. Ferdinandy P, Schulz R. Role of nitric oxide, superoxide, and peroxinitrite in myocardial ischemia-reperfusion injury and ischemic preconditioning. In: Salvemin D, Billiar TR, Vodovota Y, eds. Nitric Oxide and Inflammation. Basel: Birkhauser Verlag, 2001: 191-206.
21. Yermilov V, Rubio J, Ohshima H. Formation of 8-nitroguanin in DNA treated with peroxinitrite in vitro and its rapid removal from DNA by depurination. FEBS Lett 1995; 376: 207-210.
22. Mizoguchi H, Ogawa Y, Kanatsu K, et al. Protective effect of rebamipide on indomethacin-induced intestinal damage in rats. J Gastroenterol Hepatol 2001; 16: 1112-1119.
23. Kunitaka T, Miyazawa T, Kanatsu K, Kato S, Takeuchi K. Protective effect of thiaton, an antispasmodic drug, against indomethacin-induced intestinal damage in rats. Jpn J Pharmacol 2002; 88: 45-54.
24. Palmer RMJ, Bridge L, Foxwell NA, Moncada S. The role of nitric oxide in endothelial cell damage and its inhibition by glucocorticoids. Br J Pharmacol 1992; 105: 11-12.
25. Xia Y, Zweier JL. Superoxide anion release from inducible nitric oxide synthase. In: Salvemini D, Billiar TR, Vodovotz Y, eds. Nitric Oxide and Inflammation. Basel: Birkhauser Verlag, 2001: 27-39.